RecruitingNCT06855056
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
Validation of New Prognostic biomarkerRs in Patients With cirrhOsis diScharged After a hosPitalization Due to acutE deCompensation or acuTe-on-chronic Liver Failure
Sponsor
European Foundation for Study of Chronic Liver Failure
Enrollment
189 participants
Start Date
Mar 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the disease
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- Age between 18 and 80 years.
- Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive- related gastrointestinal bleeding, bacterial infection, or any combination of these), including those who presented ACLF during hospitalization.
- Recovery from AD and expected to be discharged within the next 48 hours.
Exclusion Criteria15
- Admission for planned diagnostic or therapeutic procedures
- Active malignancy (except for hepatocellular carcinoma within the Milan criteria or nonmelanocytic skin cancer)
- Antiviral treatment for hepatitis C, B and delta initiated in the last 6 months or planned to be initiated in the following 6 months.
- HIV positive (except undergoing treatment and who do not exhibit clinical manifestations of AIDS).
- Ongoing alcohol use disorder with an expected low adherence to prescriptions as judged by physician
- Previous liver or other organ transplantation
- Patients with TIPS or other surgical porto-caval shunts
- Chronic organic renal failure stage IV and V or estimated Glomerular Filtration Rate \<20 ml/min according to the MDRD equations
- Chronic heart failure NYHA class III or IV
- Pulmonary disease GOLD III or IV
- Patients with a history of significant extrahepatic disease with life expectancy \<6 months
- Severe psychiatric disorders
- Pregnancy and breast-feeding
- Expected low adherence to study protocol as judged by physician
- Patients who cannot provide written informed consent or refuse to participate
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06855056
Related Trials
Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement
NCT074399391 location
Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis
NCT071160962 locations
Periinterventional Coagulation Management of Patients Undergoing a TIPS
NCT044219241 location
National Liver Cancer Screening Trial
NCT0608423418 locations
Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC
NCT059711081 location